Payment overview · 2025
General Payments
$850.26
47 reported records · 11 companies
Healthcare provider profile · identity verified
Amanda Keith Smith, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · FOLEY, AL · NPI 1831328343
Verified facts
What the public records show
CMS Open Payments records show Amanda Keith Smith, M.D. received $850.26 in general payments during 2025 across 47 reported records.
AstraZeneca Pharmaceuticals LP accounted for 20.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 324 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $170.65 | 20.1% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $166.42 | 19.6% | 14 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $152.17 | 17.9% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $87.10 | 10.2% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $77.44 | 9.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $61.57 | 7.2% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $60.09 | 7.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.03 | 3.4% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $20.42 | 2.4% | 1 | 2025 |
| Sage Therapeutics, LLC | Unresolved — no canonical attribution shown | $16.72 | 2.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $8.65 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $850.26 | 47 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $156.52 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $118.54 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $104.41 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $95.42 | 9 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $87.10 | 6 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $84.45 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $77.44 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $67.72 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $60.09 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $59.95 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $46.16 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $44.56 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $44.56 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $36.67 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $29.03 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.01 | 1 | 2025 |
Source payment records
|
|||||
| ZURZUVAE Normalized: zurzuvae |
Drug | Sage Therapeutics, LLC | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $8.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 69 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 324 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 101 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
44 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
69 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
58 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
324 | 68 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
101 | 34 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 860 | 284 |
| Levothyroxine Sodium | Levothyroxine Sodium | 738 | 236 |
| Losartan Potassium | Losartan Potassium | 670 | 220 |
| Trazodone Hcl | Trazodone Hcl | 655 | 195 |
| Amlodipine Besylate | Amlodipine Besylate | 604 | 197 |
| Lisinopril | Lisinopril | 567 | 179 |
| Meloxicam | Meloxicam | 536 | 198 |
| Omeprazole | Omeprazole | 532 | 180 |
| Hydrochlorothiazide | Hydrochlorothiazide | 440 | 152 |
| Gabapentin | Gabapentin | 412 | 143 |
| Fluticasone Propionate | Fluticasone Propionate | 398 | 177 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 380 | 131 |
| Pantoprazole Sodium | Pantoprazole Sodium | 357 | 124 |
| Famotidine | Famotidine | 341 | 148 |
| Mounjaro | Tirzepatide | 324 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 320 | 108 |
| Metformin Hcl | Metformin Hcl | 297 | 104 |
| Montelukast Sodium | Montelukast Sodium | 279 | 113 |
| Pregabalin | Pregabalin | 246 | 99 |
| Zolpidem Tartrate | Zolpidem Tartrate | 229 | 72 |
| Pravastatin Sodium | Pravastatin Sodium | 211 | 72 |
| Simvastatin | Simvastatin | 208 | 62 |
| Duloxetine Hcl | Duloxetine Hcl | 201 | 74 |
| Metformin Hcl Er | Metformin Hcl | 198 | 78 |
| Sertraline Hcl | Sertraline Hcl | 188 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 183 | 70 |
| Escitalopram Oxalate | Escitalopram Oxalate | 179 | 59 |
| Furosemide | Furosemide | 179 | 64 |
| Buspirone Hcl | Buspirone Hcl | 177 | 72 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 172 | 77 |
| Metoprolol Tartrate | Metoprolol Tartrate | 165 | 49 |
| Fluoxetine Hcl | Fluoxetine Hcl | 164 | 58 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 159 | 91 |
| Alprazolam | Alprazolam | 156 | 51 |
| Bupropion Hcl Sr | Bupropion Hcl | 137 | 45 |
| Allopurinol | Allopurinol | 133 | 39 |
| Citalopram Hbr | Citalopram Hydrobromide | 130 | 44 |
| Prednisone | Prednisone | 126 | 93 |
| Estradiol | Estradiol | 122 | 53 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 118 | 40 |
| Carvedilol | Carvedilol | 115 | 41 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 115 | 38 |
| Atenolol | Atenolol | 104 | 34 |
| Ozempic | Semaglutide | 101 | 34 |
| Valacyclovir | Valacyclovir Hcl | 99 | 43 |
| Clonazepam | Clonazepam | 95 | 24 |
| Eliquis | Apixaban | 93 | 30 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 92 | 36 |
| Bupropion Xl | Bupropion Hcl | 90 | 35 |
| Potassium Chloride | Potassium Chloride | 86 | 33 |
| Ezetimibe | Ezetimibe | 83 | 33 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 83 | 26 |
| Ondansetron Odt | Ondansetron | 82 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 81 | 27 |
| Celecoxib | Celecoxib | 79 | 34 |
| Glimepiride | Glimepiride | 78 | 28 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 75 | 23 |
| Finasteride | Finasteride | 74 | 26 |
| Farxiga | Dapagliflozin Propanediol | 69 | 24 |
| Glipizide Er | Glipizide | 67 | 18 |
| Meclizine Hcl | Meclizine Hcl | 67 | 38 |
| Alendronate Sodium | Alendronate Sodium | 66 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 65 | 22 |
| Glipizide | Glipizide | 61 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 61 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 60 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 60 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 60 | 21 |
| Jardiance | Empagliflozin | 58 | 20 |
| Lovastatin | Lovastatin | 58 | 18 |
| Irbesartan | Irbesartan | 56 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 55 | 21 |
| Spironolactone | Spironolactone | 55 | 25 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 53 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 53 | 37 |
| Benazepril Hcl | Benazepril Hcl | 52 | 17 |
| Lorazepam | Lorazepam | 51 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 51 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 49 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 48 | 16 |
| Propranolol Hcl | Propranolol Hcl | 48 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 47 | 25 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 44 | suppressed |
| Synthroid | Levothyroxine Sodium | 44 | 12 |
| Azithromycin | Azithromycin | 41 | 39 |
| Fluconazole | Fluconazole | 39 | 25 |
| Sumatriptan Succinate | Sumatriptan Succinate | 39 | 11 |
| Terbinafine Hcl | Terbinafine Hcl | 38 | 19 |
| Baclofen | Baclofen | 37 | 12 |
| Methocarbamol | Methocarbamol | 37 | 17 |
| Spiriva Respimat | Tiotropium Bromide | 37 | 20 |
| Trulicity | Dulaglutide | 37 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 36 | 12 |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 34 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | 14 |
| Donepezil Hcl | Donepezil Hcl | 33 | 15 |
| Topiramate | Topiramate | 33 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 32 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 21 |
| Linzess | Linaclotide | 32 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 30 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 29 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 28 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | 12 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 28 | suppressed |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Acyclovir | Acyclovir | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 27 | 11 |
| Valsartan | Valsartan | 27 | 11 |
| Mupirocin | Mupirocin | 26 | 22 |
| Verapamil Er | Verapamil Hcl | 26 | suppressed |
| Ketoconazole | Ketoconazole | 25 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 24 |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 16 |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 21 | 16 |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Desloratadine | Desloratadine | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Glyburide | Glyburide | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $850.26 · 47 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, BREZTRI, FARXIGA, KISUNLA, Kerendia, MOUNJARO, Ozempic, QULIPTA, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, ZEPBOUND, ZURZUVAE | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error